Dawn Yates

Design, Synthesis, and Biological Evaluation of Potent and Selective Class IIa Histone Deacetylase (HDAC) Inhibitors as a Potential Therapy for Huntington’s Disease

Roland W. Bürli, Christopher A. Luckhurst, Omar Aziz et al. · Journal of Medicinal Chemistry · 2013 · 147 citations · Full text

Aldo-keto Reductase, Molecular Biology, Chemical Biology +19

Development of a Series of Aryl Pyrimidine Kynurenine Monooxygenase Inhibitors as Potential Therapeutic Agents for the Treatment of Huntington’s Disease

Leticia Toledo‐Sherman, Michael E. Prime, Ladislav Mrzljak et al. · Journal of Medicinal Chemistry · 2015 · 61 citations · Full text

Molecular Pharmacology, Medicinal Chemistry, Neurodegenerative Diseases +15

Potent, Selective, and CNS-Penetrant Tetrasubstituted Cyclopropane Class IIa Histone Deacetylase (HDAC) Inhibitors

Christopher A. Luckhurst, Perla Breccia, Andrew J. Stott et al. · ACS Medicinal Chemistry Letters · 2015 · 53 citations · Full text

Medicinal Chemistry, Heterocyclic, Biochemistry +13

Development and characterization of a CNS-penetrant benzhydryl hydroxamic acid class IIa histone deacetylase inhibitor

Christopher A. Luckhurst, Omar Aziz, Vahri Beaumont et al. · Bioorganic & Medicinal Chemistry Letters · 2018 · 45 citations

Biochemistry, Medicine, Natural Sciences +5

Assessment of Chloroquine Treatment for Modulating Autophagy Flux in Brain of WT and HD Mice

Petr Vodička, Junghyun Lim, Dana T. Williams et al. · Journal of Huntington s Disease · 2014 · 40 citations